First delivery to Swedish patients with medical cannabis oil
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“STENOCARE”) and Emerald Health Therapeutics Inc (“Emerald”) hereby announces that the first shipment and delivery of medical cannabis oil has been completed on December 23, 2020 to Sweden.
STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. The Swedish and Canadian Health authorities has completed the required certificates and the first shipment of medical cannabis oil is now being delivered to the Swedish patients. In Sweden, patients have via their doctor applied for a prescription for treatment with medical cannabis oil.
STENOCARE is a leading supplier of prescription-based medical cannabis products for patients’ treatment, and for Sweden their Canadian supplier of medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.
Niels V. Olsen, anesthesiologist, D.M.Sc., at “Smärt och Psykiatri Centrum Malmö” is commenting:
“We have been applying conventional treatment protocols to patients and find it relevant to supplement with medical cannabis for selected patients”
Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:
“With this first shipment of medical cannabis oil to Sweden we have achieved several important milestones. First, the product is the first ever medical cannabis oil product to be prescribed for treatment of Swedish patients. We look forward to following the efficacy of this treatment. Secondly, for STENOCARE it is an important milestone in our strategy to enter new markets and sell products together with our partners”
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.